Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,062 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anemia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

NCT03934450
View directory record Official record
Conditions
Malaria, Glucose 6 Phosphate Dehydrogenase Deficiency
Interventions
RPQ, SPQ, Primaquine Phosphate, Placebo
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 19, 2026, 5:30 PM EDT
Terminated No phase listed Observational

In Vivo Raman Spectroscopy of Human Capillary Beds

NCT02333136
View directory record Official record
Conditions
Anemia
Interventions
raman spectroscopy (LighTouch)
Device
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008

NCT04995315
View directory record Official record
Conditions
Pyruvate Kinase Deficiency
Interventions
Not listed
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

NCT00048035
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714
View directory record Official record
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Non-myeloablative Stem Cell Transplantation
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

NCT00002547
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cyclosporine, cytarabine, methotrexate, allogeneic bone marrow transplantation, syngeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 19, 2026, 5:30 PM EDT
Terminated Not applicable Interventional Results available

Acceptability, Feasibility and Safety of a Yoga Program for Chronic Pain in Sickle Cell Disease

NCT03694548
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Part A Survey, Part B Yoga Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
12 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

Pain Management Protocol for Pediatric Sickle Cell Disease

NCT00386048
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Brief Cognitive-Behavioral Pain Management Training
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
8 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311
View directory record Official record
Conditions
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions
darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
64
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

Developing the Family Map: Looking at Communal Coping

NCT01633021
View directory record Official record
Conditions
Sickle Cell, Diabetes, Cancer, Cardiovascular Disease, Genetic Screening
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Bethesda, Maryland • Cincinnati, Ohio • Lewisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Not yet recruiting Not applicable Interventional

The Goal is to Examine the Impact of Doula-coordinated, Midwife-delivered Postpartum Care Among Individuals With Preterm Births <34 Weeks' Gestation Requiring NICU Admission.

NCT07787845
View directory record Official record
Conditions
Doula Support, Postpartum, Postpartum Anaemia, Postpartum Depression (PPD)
Interventions
Doula-coordinated, Midwife-delivered postpartum care
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport

NCT00246077
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2007 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00093470
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia
Interventions
Clinical Observation, Tipifarnib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
339
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Managing Chronic Kidney Disease in Eastern North Carolina

NCT01054066
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Chronic Kidney Disease Education
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
1,257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 19, 2026, 5:30 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Acupressure in Patients With Sickle Cell Disease

NCT06511453
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand)
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Irvine, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

NCT01044186
View directory record Official record
Conditions
Transfusional Iron Overload
Interventions
ICL670
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Oakland, California • Orange, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

NCT01904175
View directory record Official record
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 19, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635
View directory record Official record
Conditions
MRI Scans
Interventions
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Computerized Cognitive Behavioral Therapy Assisted Life Management for Pain in Sickle Cell Disease

NCT03029468
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Pain
Interventions
cognitive behavioral therapy, eEducation
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

NCT01736397
View directory record Official record
Conditions
Iron Deficiency, Iron Deficiency Anemia
Interventions
Ferric Citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Tempe, Arizona • La Mesa, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 1 Interventional Results available

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions
Thrombosomes
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 19, 2026, 5:30 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

NCT05329649
View directory record Official record
Conditions
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 11 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Charlotte, North Carolina • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Recruiting No phase listed Observational

ATHNdataset Registry

NCT06820515
View directory record Official record
Conditions
Hemophilia, Thrombosis, Hemophilia A, Hemophilia B, Sickle Cell Disease, Glanzmann Thrombasthenia, Bleeding Disorder, Blood Disorder, Von Willebrand Diseases
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
200,000 participants
Timeline
2024 – 2055
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 19, 2026, 5:30 PM EDT